The Lancet Haematology
Fecha de publicación: June 2018
Autores: Andrés José María Ferreri
Background: Diffuse large B-cell lymphoma is diagnosed in elderly patients with increasing frequency, with 40% of diagnoses now made in patients older than 70 years. Combination therapy based on anthracycline and rituximab (ie, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) is the standard treatment regimen for diffuse large B-cell lymphoma.